KORU Medical Systems (NASDAQ:KRMD – Get Rating) and Haemonetics (NYSE:HAE – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.
Institutional & Insider Ownership
36.1% of KORU Medical Systems shares are held by institutional investors. 34.0% of KORU Medical Systems shares are held by insiders. Comparatively, 1.7% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares KORU Medical Systems and Haemonetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|KORU Medical Systems||-31.05%||-24.21%||-18.59%|
Risk & Volatility
This is a summary of current recommendations and price targets for KORU Medical Systems and Haemonetics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|KORU Medical Systems||0||0||3||0||3.00|
KORU Medical Systems presently has a consensus price target of $4.17, indicating a potential upside of 10.23%. Haemonetics has a consensus price target of $101.00, indicating a potential upside of 31.84%. Given Haemonetics’ higher probable upside, analysts clearly believe Haemonetics is more favorable than KORU Medical Systems.
Earnings & Valuation
This table compares KORU Medical Systems and Haemonetics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|KORU Medical Systems||$27.90 million||6.17||-$8.66 million||($0.20)||-18.90|
|Haemonetics||$993.20 million||3.89||$43.38 million||$1.85||41.41|
Haemonetics has higher revenue and earnings than KORU Medical Systems. KORU Medical Systems is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.
Haemonetics beats KORU Medical Systems on 10 of the 14 factors compared between the two stocks.
About KORU Medical Systems
KORU Medical Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. Its product portfolio includes FREEDOM60, FreedomEdge syringe drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. The company was founded by Andrew I. Sealfon and Adrian W. Zorgniotti on March 24, 1980 and is headquartered in Mahwah, NJ.
Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers’ ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.
Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.